Fatisol10%

Fatisol is a lipid-based component of parenteral nutrition. Its use can be classified by strength of evidence as follows:

Established / FDA-approved uses

• Source of calories and essential fatty acids as part of total or partial parenteral nutrition (PN) for patients who cannot meet their nutritional requirements through oral or enteral feeding, typically for extended periods (usually more than 5 days). This includes patients with major gastrointestinal disorders (e.g., short bowel syndrome, severe malabsorption, bowel obstruction, high-output fistulas), prolonged unconsciousness or inability to swallow, extensive burns, severe cachexia, and pre- or post-operative patients unable to tolerate adequate enteral intake.
• Prevention and treatment of essential fatty acid deficiency (EFAD) when the diet cannot provide sufficient linoleic and other essential fatty acids.

Guideline-supported / adjunct uses

• As a calorically dense, non-carbohydrate energy source within a complete parenteral nutrition regimen to reduce glucose load and associated hyperglycemia in critically ill or metabolically stressed patients, always used in combination with amino acids, dextrose, electrolytes, vitamins, and trace elements as part of the overall nutrition plan, not as a stand-alone therapy.
• Nutritional support in patients with renal impairment on restricted protein/fluid intake, as part of an individualized parenteral nutrition regimen supervised by a physician.

Fatisol is never given as a sole or isolated therapy; it is always prescribed and administered as part of a complete, physician-supervised parenteral nutrition program with appropriate laboratory monitoring.

Intravenous Fat Emulsion is a sterile, non-pyrogenic fat emulsion prepared for intravenous infusion, typically available in 10% and 20% strengths. Each formulation generally contains:

• Refined soybean oil (and in some formulations, a combination of soybean and safflower oil, or fish oil/olive oil in newer generation products) as the source of triglycerides and essential fatty acids (linoleic and alpha-linolenic acid).
• Purified egg yolk phospholipids, which act as the emulsifying agent.
• Glycerin (glycerol), added to adjust tonicity to approximately isotonic levels.
• Water for injection, with sodium hydroxide sometimes added to adjust pH.

The exact concentration and composition can vary by brand and manufacturer; the prescribing physician selects the specific product and strength appropriate for the patient.

Fatisol is a sterile, white, opaque, oil-in-water emulsion administered intravenously as part of parenteral nutrition support. It supplies a concentrated source of calories (approximately 1.1 kcal/mL for 10% emulsion and 2.0 kcal/mL for 20% emulsion) and essential fatty acids to patients who are unable to obtain adequate nutrition through the oral or enteral route.

The fat particles in Fatisol are similar in size and structure to naturally occurring chylomicrons, allowing them to be cleared from the bloodstream by the same physiological pathways (lipoprotein lipase-mediated hydrolysis) used to metabolize dietary fat.

Fatisol belongs to the therapeutic class of parenteral nutrition products (lipid/fat emulsions), used as an energy and essential fatty acid source in intravenous nutritional support regimens.

Intravenous Fat Emulsion is an oil-in-water emulsion in which triglyceride droplets are stabilized by a phospholipid emulsifier, producing particles comparable in size and composition to endogenous chylomicrons.

Mechanism

Once infused, the emulsion's triglycerides are hydrolyzed in the capillary bed by the enzyme lipoprotein lipase (present in adipose tissue, muscle, and lungs) into free fatty acids and glycerol. Free fatty acids are then taken up by peripheral tissues for oxidation (energy production), re-esterification, or storage, while glycerol is metabolized primarily in the liver. The essential fatty acids supplied (notably linoleic acid) cannot be synthesized by the body and are required for normal cell membrane structure, eicosanoid synthesis, and prevention of essential fatty acid deficiency.

Pharmacokinetics

Clearance of Intravenous Fat Emulsion from the bloodstream is dose- and rate-dependent and follows pathways similar to those for naturally occurring chylomicrons. Clearance capacity is reduced in premature infants, patients with hepatic or renal impairment, and those with sepsis or other causes of impaired lipid metabolism, which is why triglyceride monitoring is required during therapy (see Precautions and Warnings).

Fatisol is for intravenous infusion only, administered by trained healthcare personnel in a hospital or supervised clinical setting.

• May be infused through a peripheral or central vein, either alone or simultaneously with amino acid/dextrose solutions via a Y-connector, or admixed as part of a total nutrient admixture, according to institutional protocol.
• An in-line filter (typically 1.2 micron for lipid-containing admixtures) is used to reduce the risk of particulate infusion, per product-specific instructions.
• Infusion should begin slowly, with the patient observed closely during the first 15-30 minutes for any signs of an acute reaction (e.g., dyspnea, cyanosis, fever, chills, flushing).
• Do not use if the emulsion appears to be oiling out (visible oil droplets or separation) or if the container is damaged.
• Each infusion container is for single-patient, single-use only; discard any unused portion. Once a container is entered/spiked, complete the infusion within the timeframe specified by the manufacturer (generally within 24 hours).
• Do not use with in-line filters smaller than 1.2 micron, and avoid mixing with other medications in the same container unless compatibility has been specifically established.

Fatisol has the following well-established clinically significant interaction:

• Warfarin and other vitamin K-dependent anticoagulants: Soybean oil-based formulations of Fatisol contain vitamin K, which can reduce the anticoagulant effect of warfarin. Patients on concurrent anticoagulant therapy should have their coagulation status (INR) monitored more closely when Fatisol is started, adjusted, or discontinued.

Because Fatisol is typically administered alongside other components of parenteral nutrition (amino acids, dextrose, electrolytes, vitamins, trace elements, and sometimes other medications via the same line), physical and chemical compatibility must always be confirmed by the treating team or pharmacy before co-administration, as certain combinations can cause emulsion instability (e.g., "cracking" of the emulsion) rather than a true pharmacologic interaction.

Side effects of Fatisol are generally related to infusion rate and duration of therapy.

Common

• Fever, chills, or shivering during or shortly after infusion
• Nausea and vomiting
• Flushing, sweating

Less common / serious

• Hypersensitivity reactions (rash, urticaria, dyspnea, and rarely anaphylaxis)
• Elevated liver enzymes and cholestasis with prolonged use
• Thrombocytopenia or, rarely, hemolysis
• Thrombophlebitis at the infusion site (with peripheral administration)
• Fat overload syndrome (see Precautions and Warnings)

Fatisol should be used during pregnancy only if clearly needed, when adequate nutrition cannot be achieved by other means and the potential benefit to the mother justifies the potential risk to the fetus; use should be under close physician supervision with appropriate monitoring.

During lactation, Fatisol is generally not expected to pose a significant risk to a breastfed infant when used as directed as part of maternal nutritional support, but it should still be used under medical supervision, weighing individual risks and benefits. Consult a physician before use during pregnancy or breastfeeding.

Fatisol requires careful patient selection and monitoring due to the following precautions:

• Fat overload syndrome: A rare but serious complication of impaired lipid clearance, which may present as sudden clinical deterioration with fever, anemia, low platelet count, hepatosplenomegaly, and altered liver function. If suspected, the infusion should be stopped and the patient evaluated promptly.
• Triglyceride monitoring: Serum triglyceride levels should be monitored regularly during therapy, particularly in patients with risk factors for impaired lipid clearance, and the infusion rate reduced or discontinued if hypertriglyceridemia develops.
• Hepatic impairment: Patients with existing liver disease require closer monitoring, as altered lipid metabolism and risk of parenteral nutrition-associated liver disease (PNALD) are increased, particularly with prolonged use.
• Preterm and low-birth-weight infants: These patients require individualized, carefully monitored dosing; both underdosing (risking essential fatty acid deficiency) and excessive/rapid dosing (risking fat overload and, in neonates, acute respiratory distress) must be avoided.
• Infection risk: Lipid emulsions can support microbial growth; strict aseptic technique is required during preparation and administration, and infusion should be completed within the recommended timeframe.
• Egg/soy/peanut allergy: Patients with known allergy to these proteins should not receive Fatisol (see Contraindications).

Fatisol must only be administered under medical supervision as part of a complete parenteral nutrition regimen, with regular monitoring of the lipid panel, liver function tests, and overall nutritional and clinical status.

Overdose or excessively rapid infusion of Fatisol can precipitate acute fat overload syndrome or, particularly in neonates, acute respiratory distress. Signs of overdose may include marked hypertriglyceridemia, fever, liver dysfunction, and in severe cases, coagulation abnormalities or respiratory compromise.

If overdose or an acute adverse reaction is suspected, the infusion should be stopped immediately and the patient should receive prompt medical evaluation and supportive care in a hospital setting; contact emergency services or a poison control center for guidance. Do not attempt to manage a suspected overdose at home, as Fatisol is administered only in supervised clinical settings.

Store Fatisol below 25°C; do not freeze. Protect from light and keep the container in its outer carton until ready for use. Do not use if the emulsion shows signs of separation ('oiling out') or if the container is damaged. Once entered/spiked, use within the timeframe specified by the manufacturer, and discard any unused portion. Keep out of reach of children.

Pediatric patients

Fatisol is used in infants and children, including neonates, requiring parenteral nutrition, with weight-based dosing and slower infusion rates than adults (see Dosage and Administration). Preterm and low-birth-weight infants require particularly close monitoring given their limited lipid clearance capacity.

Elderly patients

Elderly patients, especially those with reduced hepatic, renal, or cardiac function, should generally be started at the lower end of the dosing range with careful monitoring.

Hepatic impairment

Patients with liver disease require closer monitoring of liver function and lipid clearance; see Precautions and Warnings.

Renal impairment

Fatisol may be used as part of an individualized nutrition regimen in patients with renal impairment, under close physician supervision.

The duration of therapy with Fatisol is determined by the treating physician based on the patient's underlying condition and ability to resume adequate oral or enteral nutrition. Parenteral nutrition, including Fatisol, is typically continued for as long as the patient is unable to meet nutritional needs by other routes, which may range from several days to weeks, or longer in patients with chronic intestinal failure. Regular reassessment of the continued need for lipid supplementation, along with laboratory monitoring, is required throughout treatment.

Intravenous Fat Emulsion belongs to the drug class of intravenous lipid emulsions / parenteral nutrition components.

Intravenous Fat Emulsion works by supplying triglyceride particles resembling natural chylomicrons that are hydrolyzed by lipoprotein lipase in peripheral tissues, releasing free fatty acids and glycerol for use as an energy source and providing essential fatty acids (such as linoleic acid) that the body cannot synthesize on its own, thereby preventing or correcting essential fatty acid deficiency while contributing calories to the parenteral nutrition regimen.

Fatisol is used in pediatric patients, including neonates and preterm infants, as a source of calories and essential fatty acids when parenteral nutrition is required. Dosing is weight-based and started at a lower initial dose and infusion rate than in adults, with gradual escalation as tolerated (see Dosage and Administration).

Preterm and low-birth-weight infants require particularly careful, individualized dosing and monitoring, since they have reduced capacity to clear infused lipid, and rapid infusion in neonates has been associated with acute respiratory distress. Safety and efficacy outside the studied age ranges and recommended dosing limits have not been established, and use in pediatric patients should always be supervised by a physician experienced in pediatric parenteral nutrition.